# US 2010/0166767 A1 · Engineered anti-il-23r antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166767 A1
- Document ID: US20100166767A1
- Status: Published application
- Kind: A1
- Application number: 12/526,544
- Filed: 2008-02-26
- Published: 2010-07-01
- Earliest claimed: 2007-02-28
- Assignees: Schering Corporation
- Inventors: Leonard G. Presta
- Web page: https://patentgrep.com/patent/US20100166767A1

## CPC

- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- C07K 16/244: {Interleukins [IL]}
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/10: Laxatives
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/24: of the sex hormones
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 29/02: without antiinflammatory effect
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- Y10S 530/809: Fused cells, e.g. hybridoma
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

Antibodies to human IL-23R are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.

## Claims

### Claim 1

A binding compound that binds to human IL-23R comprising:
a) an antibody light chain variable domain, or antigen binding fragment thereof, comprising one or more CDR sequences selected from the group consisting of SEQ ID NOs: 26-40 and 52; and
b) an antibody heavy chain variable domain, or antigen binding fragment thereof, comprising one or more CDR sequences selected from the group consisting of SEQ ID NOs: 11-25.

### Claim at position 2

2-6. (canceled)

### Claim 7 (depends on 1)

The binding compound of claim 1 comprising:
a) an antibody light chain variable domain, or antigen binding fragment thereof, comprising three CDR sequences selected from the group consisting of SEQ ID NOs: 26-40 and 52; and
b) an antibody heavy chain variable domain, or antigen binding fragment thereof, comprising three CDR sequences selected from the group consisting of SEQ ID NOs: 11-25.

### Claim at position 4

8-9. (canceled)

### Claim 10 (depends on 1)

The binding compound of claim 1 comprising:
a) a light chain variable domain, or antigen binding fragment thereof, comprising:
at least one CDRL1 from the group consisting of SEQ ID NOs: 26-30 and 52;
at least one CDRL2 from the group consisting of SEQ ID NOs: 31-35; and
at least one CDRL3 from the group consisting of SEQ ID NOs: 36-40; and
b) a heavy chain variable domain, or antigen binding fragment thereof, comprising:
at least one CDRH1 from the group consisting of SEQ ID NOs: 11-15;
at least one CDRH2 from the group consisting of SEQ ID NOs: 16-20; and
at least one CDRH3 from the group consisting of SEQ ID NOs: 21-25.

### Claim at position 6

11-12. (canceled)

### Claim 13

A binding compound that binds to human IL-23R, comprising:
a) a light chain variable domain, or antigen binding fragment thereof, comprising CDRL1, CDRL2 and CDRL3, wherein:
CDRL1 comprises the sequence of SEQ ID NO: 29 or 52 or a variant thereof;
CDRL2 comprises the sequence of SEQ ID NO: 34 or a variant thereof; and
CDRL3 comprises the sequence of SEQ ID NO: 39 or a variant thereof; and
b) a heavy chain variable domain, or antigen binding fragment thereof, comprising
CDRH1, CDRH2 and CDRH3, wherein:
CDRH1 comprises the sequence of SEQ ID NO: 14 or a variant thereof;
CDRH2 comprises the sequence of SEQ ID NO: 19 or a variant thereof; and
CDRH3 comprises the sequence of SEQ ID NO: 24 or a variant thereof;
wherein each variant comprises up to five conservatively modified amino acid substitutions.

### Claim 14 (depends on 13)

The binding compound of claim 13 wherein:
a) the light chain variable domain, or antigen binding fragment thereof, comprises a sequence selected from the group consisting of SEQ ID NOs: 48, 49 and 53; and
b) the heavy chain variable domain, or antigen binding fragment thereof, comprises a sequence selected from the group consisting of SEQ ID NOs: 45, 46 and 47.

### Claim at position 9

15-16. (canceled)

### Claim 17

A binding compound that binds to human IL-23R comprising:
a) an antibody light chain variable domain, or antigen binding fragment thereof, comprising CDRL1, CDRL2 and CDRL3, wherein:
CDRL1 comprises the sequence of SEQ ID NO: 29 or 52;
CDRL2 comprises the sequence of SEQ ID NO: 34; and
CDRL3 comprises the sequence of SEQ ID NO: 39; and
b) a heavy chain variable domain, or antigen binding fragment thereof, comprising CDRH1, CDRH2 and CDRH3, wherein:
CDRH1 comprises the sequence of SEQ ID NO: 14;
CDRH2 comprises the sequence of SEQ ID NO: 19; and
CDRH3 comprises the sequence of SEQ ID NO: 24;

### Claim at position 11

18-19. (canceled)

### Claim 20

A binding compound that binds to human IL-23R, comprising:
a) an antibody light chain variable domain, or antigen binding fragment thereof, consisting essentially of a sequence selected from the group consisting of SEQ ID NOs: 48, 49 and 53; and
b) an antibody heavy chain variable domain, or antigen binding fragment thereof, consisting essentially of a sequence selected from the group consisting of SEQ ID NOs: 45, 46 and 47.

### Claim 21

(canceled)

### Claim 22

An antibody, or antigen binding fragment thereof, that is able to block the binding of a binding compound comprising:
a) an antibody light chain variable domain comprising the sequence of SEQ ID NO: 54; and
b) an antibody heavy chain variable domain comprising the sequence of SEQ ID NO: 50,
to human IL-23R in a cross-blocking assay.

### Claim 23 (depends on 17)

An isolated nucleic acid encoding at least one of the light chain variable domain or heavy chain variable domain of the binding compound of claim 17.

### Claim 24 (depends on 23)

An expression vector comprising the nucleic acid of claim 23 operably linked to control sequences that are recognized by a host cell when the host cell is transfected with the vector.

### Claim 25 (depends on 24)

A host cell comprising the expression vector of claim 24.

### Claim 26 (depends on 25)

A method of producing a polypeptide comprising:
culturing the host cell of claim 25 in culture medium under conditions wherein the nucleic acid sequence is expressed, thereby producing polypeptides comprising the light and heavy chain variable domains; and
recovering the polypeptides from the host cell or culture medium.

### Claim 27 (depends on 17)

The binding compound of claim 17, further comprising:
a) human germline light chain framework sequences in the antibody light chain variable domain; and
b) human germline heavy chain framework sequences in the antibody heavy chain variable domain.

### Claim 28 (depends on 17)

The binding compound of claim 17, further comprising a heavy chain constant region comprising a γ1 human heavy chain constant region or a variant thereof, wherein the constant region variant comprises up to 20 conservatively modified amino acid substitutions.

### Claim 29 (depends on 17)

The binding compound of claim 17, further comprising a heavy chain constant region comprising a γ4 human heavy chain constant region or a variant thereof, wherein the constant region variant comprises up to 20 conservatively modified amino acid substitutions.

### Claim 30 (depends on 17)

The binding compound of claim 17, wherein the binding compound is an antibody fragment selected from the group consisting of Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′)2, and a diabody.

### Claim 31 (depends on 17)

A method of suppressing an immune response in a human subject comprising administering to a subject in need thereof a binding compound of claim 17, or a antigen binding fragment thereof, in an amount effective to block the biological activity of IL-23R.

### Claim 32 (depends on 31)

The method of claim 31, wherein the biological activity is an inflammatory response.

### Claim 33 (depends on 32)

The method of claim 32, wherein the subject has a disorder selected from the group consisting of arthritis, psoriasis and inflammatory bowel disease.

### Claim 34 (depends on 31)

The method of claim 31, wherein the biological activity is an autoimmune response.

### Claim 35 (depends on 34)

The method of claim 34, wherein the subject has a disorder selected from the group consisting of multiple sclerosis, systemic lupus erythematosus and diabetes.

### Claim 36 (depends on 31)

The method of claim 31, wherein the subject has cancer and the biological activity is a Th17 response.

### Claim 37

(canceled)

### Claim 38 (depends on 17)

A pharmaceutical composition comprising the binding compound of claim 17 in combination with a pharmaceutically acceptable carrier or diluent.

### Claim 39

(canceled)

### Claim 40

An antibody, or antigen binding fragment thereof, that is able to block binding of human IL-23R to the antibody deposited with ATCC under accession number PTA-7800 in a cross-blocking assay.

### Claim 41

An antibody, or antigen binding fragment thereof, that is able to block binding of human IL-23R to the antibody deposited with ATCC under accession number PTA-7801 in a cross-blocking assay.

### Claim 42 (depends on 14)

The binding compound of claim 14 wherein:
a) the light chain variable domain, or antigen binding fragment thereof, comprises the sequence of SEQ ID NO: 53, and
b) the heavy chain variable domain, or antigen binding fragment thereof, comprises the sequence of SEQ ID NO: 47.

### Claim 43 (depends on 42)

The binding compound of claim 42 comprising:
a) an antibody light chain variable domain, or antigen binding fragment thereof, comprising the sequence of SEQ ID NO: 54; and
b) an antibody heavy chain variable domain, or antigen binding fragment thereof, comprising the sequence of SEQ ID NO: 50.

### Claim 44

A binding compound that binds to human IL-23R, comprising:
a) an antibody light chain variable domain, or antigen binding fragment thereof, comprising the sequence of SEQ ID NO: 58; and
b) an antibody heavy chain variable domain, or antigen binding fragment thereof, comprising the sequence of SEQ ID NO: 57.
